VACCINES SUMMIT BOSTON 2023

www.biogatesc.com/events/vaccines-in-e/

Boston Marriott Newton Hotel, Newton, MA, USA

+91 7995794446

priyanka.m@bsc.events
ADVISORY BOARD MEMBERS

LUIS RÍOS NOGALES GARCES
EXECUTIVE VP & CDO
ILIAD BIOTECNOLOGIES, USA

SABINE HAUCK
EVP CORPORATE DEVELOPMENT
LEUKOCARE AG, GERMANY

DON J. DIAMOND
PROFESSOR
DEPARTMENT OF HEMATOLOGY & HEMATOPOIETIC CELL TRANSPLANTATION
CITY OF HOPE, USA

WILLIAM R. JACOBS JR.
LEO & JULIA FORCHHEIMER CHAIR
MICROBIOLOGY & IMMUNOLOGY
ALBERT EINSTEIN COLLEGE OF MEDICINE, USA

ORGANIZING COMMITTEE MEMBERS

SACHIN SRAVAN
FOUNDER & CEO
BIOGATE SCIENTIFIC CENTER

PRIYANKA M
PROJECT DIRECTOR - CONFERENCES
BIOGATE SCIENTIFIC CENTER

DEEP SAPARIA
EVENT CO-ORDINATOR
BIOGATE SCIENTIFIC CENTER
WELCOME MESSAGE

I want to personally welcome all of the delegates and speakers to the hub, as fellow Bostonians refer to this vibrant and pulsating city. This excellent locale for a conference brings together the very best talent in the vaccine field. While the conference site might be in Waltham, everything in the metro area is influenced by the dynamic commercial and academic environment in the hub locale. We have assembled a topnotch group of speakers and advisors to guide the content and direction of this meeting. The choice of topics spans the gamut of cutting edge science, commercial development, and clinical application of vaccines for a whole range of diseases in the global sense. Diseases of the developing world, the tropical climates, Africa and the middle east, and the western world are all covered by individual presentations by noted authorities in each of these disciplines. The meeting will cover both delivery mechanisms as well as individual vaccine examples for major disease groups plaguing our planet. Speakers come from national health agencies from Europe and the USA, large pharma represented by some of the most prestigious names, small biotechs and startups, and faculty from European and American academia. One could not ask for a more diverse group of speakers who will enlighten us on a range of topics than span the vaccine universe. I encourage anyone who is devoted to this discipline and its many allied academic and commercial applications to register to participate as this will be the highlight of the many conferences that will bombard you to attend. This is a "not to be missed" gathering that will enrich all of us, so when we return to our workplaces, we will have learned something new and cutting edge to incorporate into our own work and discoveries.

It is my great pleasure to welcome all participants to the Vaccine Summit Boston 2023. I am excited to meet colleagues from the vaccine world again on-site at this vibrant biotech community in Massachusetts. After a lean period, distinguished presenters from the USA and Europe will eventually regather in Boston to share their knowledge and experience with the vaccine community. An opportunity, that provides scientific insights combined with networking opportunities across all areas. It is this scientific exchange that helps us to develop and excel in our field. With the booster of recent years, the vaccine field emerged into new areas. The Vaccine Summit Boston 2023 will present new applications of the RNA vaccine technology for prophylactic vaccines. We will also hear how vaccines can benefit from cell therapies. I am particularly excited that this conference will also delve into therapeutic vaccination concepts, aiming to treat infectious diseases or cancer. I am looking forward to fruitful interactions among participants and to an inspiring conference.
SUPPORTERS

GOLD SPONSOR
SILVER SPONSOR
BRONZE SPONSOR

PPD®
Part of Thermo Fisher Scientific

Millipore Sigma

LAKE STREET ADVISORS

COLLABORATOR
SCHOLARLY SERVICES PARTNER

FOR SPONSORSHIP AND EXHIBITION QUERIES, PLEASE CONTACT:
SACHIN SRAVAN
Email: sachin@bsc.events

FOR SPEAKING OPPORTUNITIES AND DELEGATE SERVICES, PLEASE CONTACT:
PRIYANKA M
Email: priyanka.m@bsc.events

TARGET AUDIENCE
- C-LEVEL EXECUTIVES
- SENIOR SCIENTISTS
- DECISION MAKERS
- PRESIDENTS, VPS & SVPS
- DRUG DEVELOPERS
- ACADEMICIANS
- MANUFACTURERS
- RESEARCHERS & DEVELOPERS
- DIRECTORS
- HEALTHCARE PROFESSIONALS
- PRODUCT DEVELOPERS
- REGULATORY SPECIALISTS
- PRINCIPAL INVESTIGATORS
- CONSULTANTS

SESSION TRACKS
- NOVEL LIVE ATTENUATED VACCINES
- CANCER VACCINES
- HIV VACCINE
- COVID-19 VACCINE R&D
- INFLUENZA & RESPIRATORY
- BACTERIAL, TB & MALARIAL VACCINES
- EMERGING & RE-EMERGING DISEASES
- BIOPROCESSING & MANUFACTURING
- CLINICAL TRIALS
- VACCINES SAFETY & EFFICACY
- IMMUNE PROFILING
- NEW VACCINE DEVELOPMENT
- VACCINE ADJUVANTS
- DNA, RNA & SUBUNIT VACCINES
- VACCINE DELIVERY SYSTEMS
- VACCINES QA & QC
- VETERINARY VACCINES
- VACCINE DESIGN
CONFERENCE VENUE
COMMONWEALTH BALLROOM
BOSTON MARRIOTT NEWTON HOTEL
2345 COMMONWEALTH AVENUE
NEWTON, MA 02466, USA

MAY
22 MONDAY

08:00  Inaugural Ceremony
08:10  Keynote Talks - I
09:00  Pre-Recorded Presentation
09:30  Refreshment break - I
09:40  Session Talks - I
12:40  Lunch
13:30  Session Talks - II
16:30  Refreshment break – II
16:40  Session Talks - II (Cont.)
17:40  Poster Presentation

20:00  GALA NETWORKING DINNER

MAY
23 TUESDAY

08:00  Inaugural Ceremony
08:10  Keynote Talks - II
09:50  Refreshment break - I
10:00  Session Talks - III
13:30  Lunch
14:20  Session Talks - IV
16:20  Refreshment break – II
16:30  Session Talks - IV (Cont.)

MAY
24 WEDNESDAY

08:10  Keynote Talks - III
09:00  Session Talks - V
10:00  Refreshment break - I
10:10  Session Talks - V (Cont.)
12:40  Lunch
MAY 22
Monday

8:00-8:10  INAUGURAL CEREMONY BY DON J. DIAMOND

8:10-9:00  DON J. DIAMOND
Professor, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, USA
Title: Development of CMV-MVA-Triplex vaccine for reduction of cytomegalovirus complication post-transplantation

9:00-9:30  LUIGI BUONAGURO (PRE-RECORDED PRESENTATION)
Director, Innovative Immunological Models Unit, National Cancer Institute - IRCCS “Pascale”
Title: Viral antigens as cancer vaccines

9:40-10:10  BRUNO FANT
Chief Technical Officer, myNEO, Belgium
Title: Exploring and validating clinical validity of different sources of immunogenic targets for immunotherapy

10:10-10:40  ELI GILBOA
Dodson Professor for Microbiology & Immunology, University of Miami, USA
Title: Vaccination against a common set of neoantigens induced in tumors and pathogen infected cells

10:40-11:10  ADAM E. SNOOK
Associate Professor, Department of Pharmacology, Physiology, & Cancer Biology, Thomas Jefferson University, USA
Title: Adjuvant vaccines to prevent GI cancer recurrence

11:10-11:40  JUDITH ALAMARES-SAPUAY
Senior Scientist, Global Immunology, Vaccines R&D, Sanofi, USA
Title: Optimization and characterization of a live attenuated respiratory syncytial virus vaccine candidate

11:40-12:10  PIROUZ DAFTARIAN
Director of Scientific Engagement, Crown Bioscience, MBLI, and JSR Life Sciences, USA
Title: Today’s metrics of immunogenicity of cancer vaccines
12:10-12:40  **MARTIN MOORE**  
Founder & Chief Scientific Officer, Meissa Vaccines, USA  
Title: Safety and immunogenicity of a live, attenuated RSV vaccine in RSV-naive children 6 to 36 months of age

---

**LUNCH BREAK (50 MINS)**

---

**SESSION TALKS - II**

---

**DNA, RNA & SUBUNIT VACCINES | COVID-19 VACCINE R&D | NEW VACCINE DEVELOPMENT-I**

**Session Chair: Sarita K. Acharya**  
Principal Scientist, Global Biologics, United States Pharmacopieia, USA

---

13:30-14:00  **SARITA K. ACHARYA**  
Principal Scientist, Global Biologics, United States Pharmacopieia, USA  
Title: Ensuring quality and safety of mRNA vaccines today & tomorrow

---

14:00-14:30  **KUN ZHOU**  
Project Lead, GeneLeap Biotech, USA  
Title: A Novel mRNA-based therapeutic vaccine to target HPV16-associated cervical lesions

---

14:30-15:00  **VIRA BITKO**  
Vice President, Head of Vaccine Therapeutics, RVAC Medicines, USA  
Title: Development of RSV mRNA vaccine

---

15:00-15:30  **DON J. DIAMOND**  
Professor, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, USA representing GeoVax, USA  
Title: Assessment of Geo-CM04S1 for prevention of COVID-19 in immunocompromised cell therapy patients; An open-label safety study

---

15:30-16:00  **FENG XUAN**  
Co-founder, President & CTO, Spear Bio, USA  
Title: A novel ultrasensitive cell-free SARS-CoV-2 neutralizing antibody assay for measuring humoral immune response of vaccine with high lab-to-lab consistency

---

16:00-16:30  **URMI CHHEDA**  
Associate Scientist, GreenLight Biosciences, USA  
Title: Stability of mRNA LNP

---

**REFRESHMENT BREAK - II (10 MINS)**

---

16:40-17:10  **THORSTEN VOGL**  
Director, Technology & External Innovation, Global Immunology, Research, Sanofi, USA  
Title: Proof of concept of multivalent/octavalent vaccine platforms in naïve ferrets to deliver Influenza HA and NA antigens together for improved immunogenicity against NA compared to standard Influenza vaccines

---

17:10-17:40  **MITHILA FEROUS**  
Senior Scientist, Department of Global Immunology, Sanofi, USA  
Title: Evaluation of novel influenza mRNA vaccine supplemented with neuraminidase to improve protection against disease in ferrets

---

**POSTER PRESENTATION (30 MINS)**
Tuesday

8:00-8:10  **INAUGURAL SPEECH BY SABINE HAUCK**

8:10-9:00  **KEYNOTE TALKS - II**

8:10-9:00  **SABINE HAUCK**
EVP Corporate Development, Leukocare AG, Germany
Title: Next generation in formulation development for vaccines

9:00-9:50  **WILLIAM R. JACOBS JR.**
Leo & Julia Forchheimer Chair, Microbiology and Immunology, Albert Einstein College of Medicine, USA
Title: Current progress towards a new tuberculosis vaccine

9:00-9:50  **REFRESHMENT BREAK - I (10 MINS)**

9:50-10:30  **SESSION TALKS - III**

10:00-10:30  **AARON ESSER-KAHN**
Associate Professor, Pritzker School of Molecular Engineering, University of Chicago, USA
Title: The challenge of making every vaccine safer and more effective: Engineering signal processing of innate immune cells

10:30-11:00  **MAGDALENA TARY-LEHMANN**
Chief Scientific Officer, Cellular Technology Limited, USA
Title: Immunogenicity assessment in support of gene therapy programs - use of ELISPOT

11:00-11:30  **DE-CHU CHRISTOPHER TANG**
Chief Executive Officer, VaxDome, USA
Title: Broad-spectrum vaccine-antiviral hybrid without constraints imposed by viral mutations

11:30-12:00  **JOSEPH G. JOYCE**
Distinguished Scientist, Vaccine Process R&D (VPRD), Merck, USA
Title: Development and clinical assessment of a novel 21-valent pneumococcal conjugate vaccine (V116)

12:00-12:30  **VICTOR BRONSHTEIN**
President & CSO, Universal Stabilization Technologies (Vitrilife), USA
Title: VitriLife® technology platform for industrial production and mucosal delivery of thermostable vaccines and other biopharmaceuticals
<table>
<thead>
<tr>
<th>Time</th>
<th>Speaker</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:30-13:00</td>
<td><strong>MARK EMALFARB</strong></td>
<td>President &amp; CEO, Dyadic International, USA</td>
</tr>
<tr>
<td></td>
<td>Title: Transforming manufacturing &amp; closing the technology gap between developed and developing countries</td>
<td></td>
</tr>
<tr>
<td>13:00-13:30</td>
<td><strong>KEVIN P. KILLEEN</strong></td>
<td>Chief Scientific Officer, Matrivax, USA</td>
</tr>
<tr>
<td></td>
<td>Title: MVX01: A global, serotype-independent, pneumococcal protein fusion vaccine candidate</td>
<td></td>
</tr>
<tr>
<td>14:20-14:50</td>
<td><strong>ROBERT DILLMAN</strong></td>
<td>Chief Medical Officer, AIVITA Biomedical, USA</td>
</tr>
<tr>
<td></td>
<td>Title: Clinical progress with personal dendritic cell vaccines for cancer and covid infection</td>
<td></td>
</tr>
<tr>
<td>14:50-15:20</td>
<td><strong>VANESSA ELHARRAR</strong></td>
<td>Vice President, Vaccines Business Strategy Lead, PPD, USA</td>
</tr>
<tr>
<td></td>
<td>Title: Key considerations for vaccine development in special populations (elderly, pregnant, immuno-compromised, pediatrics)</td>
<td></td>
</tr>
<tr>
<td>15:20-15:50</td>
<td><strong>MICHAEL SUMNER</strong></td>
<td>Chief Medical Officer, Inovio, USA</td>
</tr>
<tr>
<td></td>
<td>Title: Advancing DNA medicines: Clinical updates on Ebola and recurrent respiratory papillomatosis candidates</td>
<td></td>
</tr>
<tr>
<td>15:50-16:20</td>
<td><strong>SHAHIN GHARAKHANIAN</strong></td>
<td>MD Consulting LLC, CIC: Cambridge Innovation Center, USA</td>
</tr>
<tr>
<td></td>
<td>Title: P28GST, a therapeutic vaccine for the treatment of chronic inflammatory diseases. Data supporting clinical indication and case study</td>
<td></td>
</tr>
<tr>
<td>16:30-17:00</td>
<td><strong>LYNDA TUSSEY</strong></td>
<td>Chief Development Officer, Vaxess Technologies, USA</td>
</tr>
<tr>
<td></td>
<td>Title: Phase 1 clinical evaluation of VX-103: A sustained-release, patch-based influenza vaccine delivered on the MIMIXTM platform</td>
<td></td>
</tr>
<tr>
<td>17:00-17:30</td>
<td><strong>JAMES Z. DENG</strong></td>
<td>Associate Principal Scientist, Vaccine Analytical R&amp;D, Merck, USA</td>
</tr>
<tr>
<td></td>
<td>Title: Analytical strategies for characterization of multi-valent pneumococcal conjugate vaccine</td>
<td></td>
</tr>
<tr>
<td>17:30-18:00</td>
<td><strong>MIC MCGOLDRICK</strong></td>
<td>Associate Director Global CMC Policy, Merck&amp;Co., Inc. on behalf of IFPMA, USA</td>
</tr>
<tr>
<td></td>
<td>Title: Accelerating access to vaccines – Next steps beyond the pandemic</td>
<td></td>
</tr>
<tr>
<td>18:00-18:30</td>
<td><strong>MATTHEW A. COLEMAN</strong></td>
<td>Staff Scientist, Lawrence Livermore National Laboratory, USA</td>
</tr>
<tr>
<td></td>
<td>Title: Co-translational cell-free expression of Chlamydial membrane bound proteins for antigen discovery and application</td>
<td></td>
</tr>
</tbody>
</table>
**MAY 24 Wednesday**

**KEYNOTE SESSION - III**

8:10–9:00  
**ADRIAN V. S. HILL**  
Director, The Jenner Institute, University of Oxford, UK  
Title: Phase 3 progress with a high efficacy malaria vaccine

**SESSION TALKS - V**

**INFLUENZA & RESPIRATORY | BACTERIAL, TB & MALARIAL VACCINES | VETERINARY VACCINES**  
**EMERGING & RE-EMERGING DISEASES**

Session Chair: Trudy Morrison  
Professor, University of Massachusetts Chan Medical School, USA

9:00–9:30  
**TRUDY MORRISON**  
Professor, University of Massachusetts Chan Medical School, USA  
Title: The Respiratory syncytial virus G protein enhances the immune responses to the RSV F protein in an enveloped virus-like particle vaccine candidate

9:30–10:00  
**CHRISTOPHER P. LOCHER**  
Co-Founder & CEO, Versatope Therapeutics, USA  
Title: Structure and function of a broad-strain influenza vaccine using nano-vesicles

**REFRESHMENT BREAK - I (10 MINS)**

10:10–10:40  
**JUN LIN**  
Professor of Infectious Disease, The University of Tennessee, USA  
Title: Enterobactin-based immune intervention against Gram-negative pathogens

10:40–11:10  
**SELVAKUMAR SUBBIAN**  
Principal Investigator, Public Health Research Institute, New Jersey Medical School, Rutgers University, USA  
Title: Immune response of BCG vaccination is shaped by the nature and infectious inoculum of pathogenic *Mycobacterium tuberculosis*

11:10–11:40  
**CHINNASWAMY JAGANNATH**  
Professor, Pathology & Genomic Medicine, Houston Methodist Research Institute & Weill Cornell Medical College, USA  
Title: New generation adenoviral and mRNA-based tuberculosis vaccines

11:40–12:10  
**DEEPAK KAUSHAL**  
Professor, Senior Leadership Member of the SNPRC, Texas Biomedical Research Institute, USA  
Title: Prevention of tuberculosis in a second species of nonhuman primates by an attenuated, stress-response deficient mutant of *Mycobacterium tuberculosis*

12:10–12:40  
**JOSEPH M. VINETZ**  
Professor of Medicine (Infectious Diseases), Yale University School of Medicine, USA  
Title: Exploiting bacterial genomics to delineate mechanisms of pathogenesis, enabling vaccine development for an emerging/re-emerging zoonotic infectious disease

**LUNCH BREAK (60 MINS)**
POSTER SESSION

POSTER-01  ANDREW J. RENNEKAMP
Medical Science Liaison, CSL Seqirus, USA
Title: Real world study of adjuvanted influenza vaccine in preventing cardio-respiratory related hospitalizations in the elderly during the 2019-2020 U.S. influenza season

POSTER-02  MARK EMALFARB
President & CEO, Dyadic International, USA
Title: Development of the thermophilic filamentous fungus Thermothelomyces heterothallica C1 into a prominent human and animal vaccines production platform

POSTER-03  ABEL E. VASQUEZ
Head Biotechnology Section, Public Health Institute of Chile, Universidad del Alba, Santiago, Chile.
Title: The surface immunogenic recombinant protein from Streptococcus agalactiae is a potential new vaccine adjuvant

POSTER-04  KAROLYNE WARNY
Senior Research Associate, Global Immunology, Sanofi, USA
Title: Preclinical benefit of recombinant NA addition to HA-based protein vaccine reduced disease severity in a ferret challenge model

Thank you